Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.03
DGX's Cash to Debt is ranked lower than
98% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. DGX: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
DGX' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.03
Equity to Asset 0.46
DGX's Equity to Asset is ranked lower than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DGX: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
DGX' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.46
0.3
0.62
Interest Coverage 9.92
DGX's Interest Coverage is ranked lower than
65% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. DGX: 9.92 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 11.69
Current: 9.92
5.74
11.69
F-Score: 8
Z-Score: 3.22
M-Score: -2.41
WACC vs ROIC
5.04%
11.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.00
DGX's Operating margin (%) is ranked higher than
89% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. DGX: 19.00 )
Ranked among companies with meaningful Operating margin (%) only.
DGX' s Operating margin (%) Range Over the Past 10 Years
Min: 13.22  Med: 17.22 Max: 20.64
Current: 19
13.22
20.64
Net-margin (%) 9.98
DGX's Net-margin (%) is ranked higher than
79% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. DGX: 9.98 )
Ranked among companies with meaningful Net-margin (%) only.
DGX' s Net-margin (%) Range Over the Past 10 Years
Min: 5.07  Med: 8.69 Max: 11.88
Current: 9.98
5.07
11.88
ROE (%) 16.71
DGX's ROE (%) is ranked higher than
86% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. DGX: 16.71 )
Ranked among companies with meaningful ROE (%) only.
DGX' s ROE (%) Range Over the Past 10 Years
Min: 10.72  Med: 16.28 Max: 20.93
Current: 16.71
10.72
20.93
ROA (%) 7.43
DGX's ROA (%) is ranked higher than
81% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. DGX: 7.43 )
Ranked among companies with meaningful ROA (%) only.
DGX' s ROA (%) Range Over the Past 10 Years
Min: 4.78  Med: 7.00 Max: 10.69
Current: 7.43
4.78
10.69
ROC (Joel Greenblatt) (%) 93.90
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. DGX: 93.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DGX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 88.63  Med: 117.16 Max: 143.99
Current: 93.9
88.63
143.99
Revenue Growth (3Y)(%) 3.80
DGX's Revenue Growth (3Y)(%) is ranked lower than
51% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. DGX: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DGX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 8.10 Max: 15.4
Current: 3.8
0
15.4
EBITDA Growth (3Y)(%) 4.20
DGX's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. DGX: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DGX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.30 Max: 44.4
Current: 4.2
0
44.4
EPS Growth (3Y)(%) 7.50
DGX's EPS Growth (3Y)(%) is ranked higher than
61% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.60 vs. DGX: 7.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DGX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.40 Max: 61.5
Current: 7.5
0
61.5
» DGX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

DGX Guru Trades in Q2 2015

Joel Greenblatt 281,305 sh (+395.39%)
Paul Tudor Jones 17,768 sh (+23.01%)
John Rogers 580,555 sh (+12.52%)
Murray Stahl 7,550 sh (+0.67%)
Bernard Horn 61,733 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
T Rowe Price Equity Income Fund Sold Out
Chuck Royce Sold Out
Jeff Auxier 72,970 sh (-0.07%)
Charles Brandes 172,331 sh (-1.36%)
Chris Davis 4,980,482 sh (-1.74%)
Pioneer Investments 531,519 sh (-5.49%)
David Dreman 19,971 sh (-7.34%)
John Hussman 200,000 sh (-9.09%)
Ray Dalio 70,389 sh (-52.47%)
Jim Simons 54,200 sh (-90.72%)
» More
Q3 2015

DGX Guru Trades in Q3 2015

Scott Black 111,006 sh (New)
Ray Dalio 236,592 sh (+236.12%)
Joel Greenblatt 600,031 sh (+113.30%)
Jim Simons 107,620 sh (+98.56%)
John Rogers 695,732 sh (+19.84%)
Bernard Horn 61,733 sh (unchged)
Murray Stahl 7,550 sh (unchged)
Jeff Auxier 72,820 sh (-0.21%)
David Dreman 19,914 sh (-0.29%)
Charles Brandes 170,422 sh (-1.11%)
Paul Tudor Jones 17,360 sh (-2.30%)
Chris Davis 4,203,791 sh (-15.59%)
John Hussman 127,000 sh (-36.50%)
Pioneer Investments 216,947 sh (-59.18%)
» More
Q4 2015

DGX Guru Trades in Q4 2015

Pioneer Investments 220,556 sh (+1.66%)
Bernard Horn 61,733 sh (unchged)
Jim Simons Sold Out
John Rogers 693,253 sh (-0.36%)
Charles Brandes 168,985 sh (-0.84%)
David Dreman 19,614 sh (-1.51%)
Murray Stahl 7,350 sh (-2.65%)
Jeff Auxier 70,270 sh (-3.50%)
Chris Davis 3,590,857 sh (-14.58%)
Paul Tudor Jones 10,548 sh (-39.24%)
Joel Greenblatt 270,275 sh (-54.96%)
Scott Black 35,253 sh (-68.24%)
Ray Dalio 64,399 sh (-72.78%)
John Hussman 2,000 sh (-98.43%)
» More
Q1 2016

DGX Guru Trades in Q1 2016

Murray Stahl 7,350 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Aug 07, 2014

The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

The Best Companies of the Medical Industry – September 2015 Five companies identified as suitable for defensive and enterprising investors
While ModernGraham supports the bottom-up approach to investing, many investors do utilize the top-down method, whereby an industry is selected before the company itself. With that in mind, here is a look at the best companies of the medical industry, selecting the most promising investment opportunities within that industry and giving a broad look at the industry as a whole. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.60
DGX's P/E(ttm) is ranked higher than
82% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.31 vs. DGX: 14.60 )
Ranked among companies with meaningful P/E(ttm) only.
DGX' s P/E(ttm) Range Over the Past 10 Years
Min: 9.14  Med: 17.70 Max: 31.21
Current: 14.6
9.14
31.21
Forward P/E 14.03
DGX's Forward P/E is ranked higher than
88% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.92 vs. DGX: 14.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.60
DGX's PE(NRI) is ranked higher than
82% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.12 vs. DGX: 14.60 )
Ranked among companies with meaningful PE(NRI) only.
DGX' s PE(NRI) Range Over the Past 10 Years
Min: 9.53  Med: 15.98 Max: 23.27
Current: 14.6
9.53
23.27
Price/Owner Earnings (ttm) 16.14
DGX's Price/Owner Earnings (ttm) is ranked higher than
78% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.08 vs. DGX: 16.14 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DGX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.61  Med: 25.31 Max: 84.87
Current: 16.14
11.61
84.87
P/B 2.31
DGX's P/B is ranked higher than
65% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. DGX: 2.31 )
Ranked among companies with meaningful P/B only.
DGX' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 2.49 Max: 4.31
Current: 2.31
1.85
4.31
P/S 1.45
DGX's P/S is ranked higher than
76% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. DGX: 1.45 )
Ranked among companies with meaningful P/S only.
DGX' s P/S Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.18
Current: 1.45
1.03
2.18
PFCF 16.83
DGX's PFCF is ranked higher than
76% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.30 vs. DGX: 16.83 )
Ranked among companies with meaningful PFCF only.
DGX' s PFCF Range Over the Past 10 Years
Min: 8.25  Med: 13.84 Max: 21.76
Current: 16.83
8.25
21.76
POCF 12.08
DGX's POCF is ranked higher than
71% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.11 vs. DGX: 12.08 )
Ranked among companies with meaningful POCF only.
DGX' s POCF Range Over the Past 10 Years
Min: 6.99  Med: 10.90 Max: 14.48
Current: 12.08
6.99
14.48
EV-to-EBIT 11.74
DGX's EV-to-EBIT is ranked higher than
79% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. DGX: 11.74 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 10.70 Max: 15.1
Current: 11.74
7.4
15.1
EV-to-EBITDA 9.51
DGX's EV-to-EBITDA is ranked higher than
71% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.76 vs. DGX: 9.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 8.80 Max: 11.9
Current: 9.51
6.2
11.9
PEG 3.48
DGX's PEG is ranked lower than
63% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. DGX: 3.48 )
Ranked among companies with meaningful PEG only.
DGX' s PEG Range Over the Past 10 Years
Min: 0.81  Med: 1.45 Max: 5.21
Current: 3.48
0.81
5.21
Shiller P/E 19.65
DGX's Shiller P/E is ranked higher than
93% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.90 vs. DGX: 19.65 )
Ranked among companies with meaningful Shiller P/E only.
DGX' s Shiller P/E Range Over the Past 10 Years
Min: 14.43  Med: 19.73 Max: 38.66
Current: 19.65
14.43
38.66
Current Ratio 1.37
DGX's Current Ratio is ranked lower than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. DGX: 1.37 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.25 Max: 2.15
Current: 1.37
0.74
2.15
Quick Ratio 1.29
DGX's Quick Ratio is ranked lower than
75% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. DGX: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.03
Current: 1.29
0.7
2.03
Days Inventory 7.35
DGX's Days Inventory is ranked higher than
95% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. DGX: 7.35 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.93  Med: 7.75 Max: 8.46
Current: 7.35
6.93
8.46
Days Sales Outstanding 46.23
DGX's Days Sales Outstanding is ranked higher than
70% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. DGX: 46.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 46.23
40.51
48.01
Days Payable 21.96
DGX's Days Payable is ranked lower than
85% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. DGX: 21.96 )
Ranked among companies with meaningful Days Payable only.
DGX' s Days Payable Range Over the Past 10 Years
Min: 16.4  Med: 18.43 Max: 21.87
Current: 21.96
16.4
21.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.05
DGX's Dividend Yield is ranked higher than
75% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.38 vs. DGX: 2.05 )
Ranked among companies with meaningful Dividend Yield only.
DGX' s Dividend Yield Range Over the Past 10 Years
Min: 0.6  Med: 0.81 Max: 2.46
Current: 2.05
0.6
2.46
Dividend Payout 0.31
DGX's Dividend Payout is ranked higher than
57% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. DGX: 0.31 )
Ranked among companies with meaningful Dividend Payout only.
DGX' s Dividend Payout Range Over the Past 10 Years
Min: 0.09  Med: 0.13 Max: 0.91
Current: 0.31
0.09
0.91
Dividend Growth (3y) 42.30
DGX's Dividend Growth (3y) is ranked higher than
91% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. DGX: 42.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
DGX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.80 Max: 55.4
Current: 42.3
0
55.4
Forward Dividend Yield 2.13
DGX's Forward Dividend Yield is ranked higher than
70% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.35 vs. DGX: 2.13 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 8.30
DGX's Yield on cost (5-Year) is ranked higher than
99% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. DGX: 8.30 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DGX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.44  Med: 3.30 Max: 10.01
Current: 8.3
2.44
10.01
3-Year Average Share Buyback Ratio 3.20
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.30 vs. DGX: 3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.7  Med: 2.60 Max: 0
Current: 3.2
-17.7
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.05
DGX's Price/Projected FCF is ranked higher than
86% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. DGX: 1.05 )
Ranked among companies with meaningful Price/Projected FCF only.
DGX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 0.84 Max: 3.77
Current: 1.05
0.65
3.77
Price/DCF (Earnings Based) 1.36
DGX's Price/DCF (Earnings Based) is ranked higher than
79% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. DGX: 1.36 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.07
DGX's Price/Median PS Value is ranked lower than
57% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. DGX: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
DGX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.02 Max: 1.66
Current: 1.07
0.24
1.66
Price/Peter Lynch Fair Value 2.70
DGX's Price/Peter Lynch Fair Value is ranked lower than
64% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. DGX: 2.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DGX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.62  Med: 1.32 Max: 4.3
Current: 2.7
0.62
4.3
Earnings Yield (Greenblatt) (%) 8.50
DGX's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. DGX: 8.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DGX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6.6  Med: 9.30 Max: 13.6
Current: 8.5
6.6
13.6
Forward Rate of Return (Yacktman) (%) 11.08
DGX's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. DGX: 11.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DGX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10.3  Med: 17.45 Max: 27.6
Current: 11.08
10.3
27.6

More Statistics

Revenue(Mil) $7517
EPS $ 5.15
Beta0.53
Short Percentage of Float5.81%
52-Week Range $59.66 - 89.00
Shares Outstanding(Mil)141.46

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 7,564 7,720 7,992
EPS($) 5.09 5.36 5.72
EPS without NRI($) 5.09 5.36 5.72

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:TMO, NYSE:A, TSE:6869, NYSE:LH, XSWX:LONN » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Royce Special Equity Multi-Cap Fund Mar 22 2016 
Baron Growth Fund New Purchases Part 3 Feb 08 2016 
Popular Guru Stocks With High, Growing Yield Feb 03 2016 
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
Brian Rogers Buys Occidental Petroleum, Tyco In Q2 Jul 16 2015 
Vermillion (VRML) Ovarian Cancer Test Mega-deal; Papa Murphy's Holdings (FRSH) and Wix (WIX) Strong Mar 18 2015 
Charles Brandes' Top Buys During Q4 Feb 11 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 
DGX: A Healthy Diagnosis Oct 08 2014 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 

More From Other Websites
First widely available Zika test OK'd for emergency use Apr 29 2016
First widely available Zika test OK'd for emergency use Apr 29 2016
ETF’s with exposure to Quest Diagnostics, Inc. : April 29, 2016 Apr 29 2016
First US Zika death reported in Puerto Rico Apr 29 2016
Alere, Caterpillar, and Delta Air Lines Among 5 of the Day’s High Volume Movers Apr 29 2016
2:21 am Quest Diagnostics receives FDA Emergency Use Authorization for the Zika Virus RNA... Apr 29 2016
Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use Apr 28 2016
Quest Diagnostics says its Zika virus test gets U.S. approval Apr 28 2016
Understanding Quest Diagnostics’ Valuation Multiple Compared to Those of Peers Apr 28 2016
QUEST DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report Apr 27 2016
Quest Diagnostics, Inc. :DGX-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 25 2016
Analysts: Quest Likely to Do Deals First, Stock Buybacks Second, with Focus Sale Proceeds Apr 22 2016
Opening Bell, April 22, 2016 Apr 22 2016
Today's Bell Ringer, April 22, 2016 Apr 22 2016
Edited Transcript of DGX earnings conference call or presentation 21-Apr-16 12:30pm GMT Apr 21 2016
Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up Apr 21 2016
Quest Diagnostics Inc Earnings Call scheduled for 8:30 am ET today Apr 21 2016
Quest Diagnostics (DGX) Q1 Earnings Meet, Revenues Top Apr 21 2016
Q1 2016 Quest Diagnostics Inc Earnings Release - Before Market Open Apr 21 2016
Quest Diagnostics meets 1Q profit forecasts Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK